Just before ringing in the new year, Valeant has managed to resolve another crisis.
From around 2014 through 2016, Canadian drug company Valeant seemingly had a crisis story every week, ranging from insider trading to channel stuffing. Now, Pershing Square, a hedge fund run by activist investor William Ackman, and Valeant, decided to settle an insider trading lawsuit with Allergan and pay $290 million. Valeant has many other hurdles ahead but it’s nice to know they’ve crossed another thing off the list.
Here’s a roundup of these stories and other top legal news from the past month.
- Arrogance and Greed: Ackman, Valeant Pay $290M to End Allergan Insider Trading Lawsuit
- Pharma Bro Shkreli’s Ex-Lawyer Convicted of Helping Him Defraud Pharma Firm
- United Therapeutics to Pay $210M to Resolve U.S. Kickback Probe
- North Carolina Sues Insys Accused of Bribing Doctors to Prescribe Powerful Opioid Spray
Read More From Karl Thiel:
Can 2018 Possibly Rival 2017’s Biotechs Record Venture Capital Splurge?
